Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020

Explore key factors influencing future expectations for the production of evidence of relative effectiveness (RE) for drugs in Europe in 2020; construct three plausible future scenarios for RE evidence generation. Semi-structured key informant interviews and three rounds of modified Delphi to gather...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative effectiveness research 2015-08, Vol.4 (4), p.401-418
Main Authors: Towse, Adrian, Garau, Martina, Mohr, Penny, Messner, Donna A
Format: Article
Language:English
Subjects:
adaptive licensing
Comparative Effectiveness Research - methods
coverage with evidence development
Delphi Technique
Drug approval
drug development
Drug discovery
Drug Discovery - methods
electronic health records
Europe
Forecasts and trends
HTA methods
Humans
Interviews as Topic
Laws, regulations and rules
performance-based risk sharing agreements
Prescription Drugs
relative effectiveness
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Explore key factors influencing future expectations for the production of evidence of relative effectiveness (RE) for drugs in Europe in 2020; construct three plausible future scenarios for RE evidence generation. Semi-structured key informant interviews and three rounds of modified Delphi to gather expert perspectives and develop future scenarios. Most influential factors were degree of regulator use of postmarketing authorization (postlaunch) efficacy studies and adaptive licensing; degree of pan-European health technology assessment body coordination in reviewing prelaunch evidence and demanding postlaunch studies; the nature of regulator - health technology assessment body interaction. The most likely scenario entailed some change with postlaunch regulatory studies driving the likely nature of RE evidence generated.
ISSN:2042-6305
2042-6313
DOI:10.2217/cer.15.7